-
Half of the world's esophageal cancer is in China, and the standard diagnosis and treatment points are here!
Time of Update: 2022-06-01
Update based on study: The CheckMate-649 study is a randomized, open-label, global, phase III study evaluating nivolumab in combination with chemotherapy versus chemotherapy alone in advanced or metastatic gastric cancer, gastroesophageal junction Efficacy and safety of first-line treatment of carcinoma and esophageal adenocarcinoma in the global population .
-
"The Lancet" is heavy: precise excision, better survival!
Time of Update: 2022-06-01
The results of the study confirm that a more precise method of resection, segmentectomy (removal of only one segment of a patient's lung), may be more effective than lobectomy in improving overall survival in patients with early-stage lung cancer .
-
Worried about colon cancer but afraid to do colonoscopy?
Time of Update: 2022-05-31
It can be seen from the research results that the cancer detection rate of FIT is similar to that of colonoscopy, and subjects in the FIT group are more likely to be screened; in addition, prior FIT examination can help patients reduce the number of colonoscopy and pain .
-
A breakthrough in lung cancer immune neoadjuvant, CheckMate-816 achieves the dual endpoints of EFS and pCR, opening a new model for early-stage lung cancer treatment!
Time of Update: 2022-05-31
At the just-concluded 2022 American Association for Cancer Research (AACR) annual meeting, CheckMate-816, a phase III study of nivolumab combined with chemotherapy in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC), announced the primary endpoint of event-free survival.
-
Targeting cancer stem cell antigens: novel dual antibodies have great potential
Time of Update: 2022-05-31
In conclusion, the research and development idea of MCLA-158 is extremely novel, focusing on the antigen targets of cancer stem cells, constructing double antibodies with EGFR and HER3, and screening candidate double antibody molecules through tumor organoids .
-
Sintilimab is included in the guidelines of the Chinese Society of Clinical Oncology (CSCO) for the first-line treatment of five major tumor types
Time of Update: 2022-05-31
Together with the first-line treatment recommendations that have been included in the "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer", the national first-line innovative drug sintilimab has achieved a breakthrough in the inclusion of the first-line treatment of five tumor types in the CSCO guidelines .
-
Professor Wu Yilong led the way: How to break the situation after EGFR mutation lung cancer targeted therapy resistance?
Time of Update: 2022-05-31
On this basis, in March 2021, the Lung Oncology Branch of the Guangdong Medical Association and the Guangdong Clinical Trials Association/China Thoracic Oncology Research Assistance Group (GACT/CTONG) will organize various specialties in the clinical field of lung cancer in Guangdong Province.
-
Express $25 million to help develop a new generation of synthetic lethal therapy, Pfizer reaches R&D cooperation
Time of Update: 2022-05-31
Pfizer and Zentalis have entered into an agreement to collaborate to advance the clinical development of selective Wee1 inhibitors, an innovative therapy that uses the principle of synthetic lethality to kill cancer cells .
-
Can immunotherapy challenge again after severe immune-related hepatitis?
Time of Update: 2022-05-31
(If you need the original text of the literature, you can add the editor's WeChat yxj_oncology to get it) ▎Clinical question: What is the outcome of patients who re-accepted immunotherapy after remission of severe immune-related hepatitis?
-
According to the innovative mechanism, taking advantage of the policy wind, Professor Ma Jun shares the new thinking of lymphoma treatment in the new era
Time of Update: 2022-05-31
On this occasion, Yimaitong specially invited Professor Ma Jun, director of the Harbin Institute of Hematology and Oncology, to interpret the significance of the summit forum, review the history of lymphoma immunotherapy, grasp the frontier progress in the field of lymphoma, and look forward to the feasible way of lymphoma treatment in the future .
-
Professor Ye Dingwei: Immunotherapy is out of the circle and solves the problem of urothelial cancer
Time of Update: 2022-05-31
Coinciding with the conclusion of the 2022 CSCO Guideline Conference, Yimaitong was honored to invite Professor Ye Dingwei, Vice President of Fudan University Affiliated Cancer Hospital, to analyze the advantages of immunotherapy in the adjuvant treatment of MIUC, and look forward to the future development trend of immunotherapy for urothelial carcinoma .
-
MET amplification resistance in patients with EGFR-mutant advanced lung cancer after multi-line therapy?
Time of Update: 2022-05-31
TATTON[6] is a multi-arm, multi-center, open-label, four-part (AD), phase Ib study to investigate the effect of osimertinib combined with sivotinib in the treatment of EGFR-TKIs-resistant MET amplification/overexpression Efficacy and safety of patients with EGFR-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC) .
-
Universal CAR-NKT therapy announces the latest clinical data, still effective in CAR-T therapy for relapsed patients
Time of Update: 2022-05-31
Recommended reading: Cell sub-issue: Super-powered natural killer cell CAR-iNKT, a more effective "spot" immunotherapy for cancerYimai Meng broke the news In September 2019, researchers at UCLA made a new progress, they Using genetically engineered human hematopoietic stem cells to generate iNKT cells for cancer therapy effectively inhibits tumor growth in mice with multiple myeloma and melanoma .
-
2022 ASCO Voice of China｜A total of 34 Chinese studies were selected in the clinical science forum, oral presentations, and poster discussions!
Time of Update: 2022-05-31
The ASCO Annual Meeting is the world's largest, most academically advanced and most authoritative clinical oncology meeting dedicated to cancer prevention, treatment and improved patient management.
: 3000 Title: A phase Ia/Ib study of CBP-1008, Reporter: Qiu Haibo Unit: Sun Yat-sen University Cancer Center Abstract No.
-
Express first-line treatment of esophageal cancer, BeiGene/Novartis PD-1 antibody combination therapy achieves the primary endpoint of Phase 3 clinical trials
Time of Update: 2022-05-31
▎WuXi AppTec content team editor Today, BeiGene and Novartis announced that the anti-PD-1 antibody tislelizumab (tislelizumab, Chinese brand name Bai Zean) in combination with chemotherapy, in the first-line treatment of advanced stage or met the primary endpoint in a phase 3 clinical trial in patients with metastatic esophageal squamous cell carcinoma (ESCC) .
-
CD: Chinese scientists break the predicament of liver cancer immunotherapy resistance!
Time of Update: 2022-05-31
Overall, the research team of Academician Fan Jia/Zhu Di/Xu Yang found that IFN-α+PD-1 blockade combination therapy can significantly inhibit tumor growth in liver cancer mice or HCC patients .
-
Research reveals the mechanism of chemotherapy resistance in small cell lung cancer and strategies to overcome it
Time of Update: 2022-05-31
This study revealed the function and mechanism of mevalonate (MVA)-geranylgeranyl diphosphate (GGPP) metabolic pathway in chemoresistance in small cell lung cancer, and proposed a new strategy for targeted therapy .
-
Express AstraZeneca/Daiichi Sankyo's blockbuster ADC won the 5th breakthrough therapy designation for the treatment of HER2 low-expressing breast cancer
Time of Update: 2022-05-31
In DESTINY-Breast04, Enhertu provided a clinically meaningful survival benefit in patients with metastatic breast cancer with low HER2 expression .
” Reference: [1] ENHERTU® Granted Breakthrough Therapy Designation in US for Patients with HER2 Low Metastatic Breast Cancer.
-
Fast delivery improves activity and durability, and a new generation of ready-to-use CAR-T therapy is granted orphan drug designation by the FDA
Time of Update: 2022-05-30
S. FDA has granted orphan drug designation (ODD) for the investigational CAR-T therapy ALLO-605 for the treatment of multiple myeloma .
" Reference: Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR T Cell Product Candidate, for the Treatment of Multiple Myeloma.
-
Allogene Generic BCMA CAR-T Therapy Receives FDA Orphan Drug Designation
Time of Update: 2022-05-30
Recommended reading: The "most" safe CAR-T has been granted regenerative medicine advanced therapy (RMAT) qualification by the US FDAYimai Meng broke the newsOn November 12, 2021, Cellectis announced its allogeneic CAR at the annual meeting of the Cancer Immunotherapy Society - First preclinical data on T-cell UCARTMESO for the treatment of solid tumors expressing mesothelin (MSLN) .
